What is the primary purpose of Samsung Biologics' $2.1 billion rights offering?

The primary purpose is to raise approximately 3 trillion South Korean won ($2.1 billion) to accelerate Samsung Biologics’ long-term growth strategy, specifically funding the acquisition of PolyPeptide Group AG and further development of Bio Campus II in South Korea.

How will the proceeds from the rights offering be allocated between the PolyPeptide acquisition and domestic expansion?

Approximately 2.7 trillion won will finance the proposed acquisition of PolyPeptide Group AG — for which Samsung Biologics made an all-cash offer of CHF1.46 billion — while the remaining 290 billion won will support further development of Bio Campus II, including the sequential launch of plants No. 6 through No. 8 to boost global manufacturing capacity to 1.38 million liters by 2032.

Samsung Biologics launches $2B rights offering to fund expansion

Sep 1, 2026

Samsung Biologics launched a $2.1 billion rights offering to acquire PolyPeptide Group and expand Bio Campus II capacity. The investment targets peptide-based therapeutics and antibodies, aiming to reach 1.38 million liters of global production by 2032.

chemweek

2026-07-22

Samsung Makes $1.8 Billion Bet on Peptide Production

2026-09-01

Samsung Biologics launches $2B rights offering to fund expansion

Samsung Biologics launches $2B rights offering to fund expansion

FAQ